Geovax Labs, INC 10-Q quarterly reports

GeoVax Labs reports reduced operating expenses in Q2 2026, with a net loss of $4.4 million, as the company prioritizes its mpox/smallpox and oncology vaccine candidates.

GeoVax Labs reports reduced operating expenses and net loss in Q1 2026, with continued focus on vaccine development and ongoing capital raising efforts.

GeoVax Labs reported increased net losses and a going concern warning for Q3 2025, despite raising significant capital and advancing its vaccine and immunotherapy pipeline.

GeoVax Labs, Inc. reported a substantial net loss and increased cash burn for Q2 2025, coupled with the termination of a key government contract, raising significant doubt about its ability to continue as a going concern, despite recent equity financings.

GeoVax Labs reports increased revenue in Q1 2025 due to a government contract but faces financial uncertainty following the contract's termination.

GeoVax Labs saw a significant increase in revenue due to a BARDA contract, while continuing to advance its vaccine and immunotherapy programs.

GeoVax Labs announced its Q2 2024 financial results, highlighted by a new BARDA contract to advance its COVID-19 vaccine, while also noting ongoing financial challenges.

GeoVax Labs reported a net loss of $5.85 million for the first quarter of 2024 and expressed concerns about its ability to continue as a going concern without additional funding.